Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Ligand-Induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4. | ChemMedChem | 2026 | 41932680 | PubTator, text mining | PubMed |
| The Multifaceted Legacy of Thalidomide: Chemistry and Biology Driving Modern Drug Design. | ChemMedChem | 2026 | 41931005 | PubTator, text mining | PubMed |
| New PROTAC Designs for Targeted Protein Degradation in 2021-2025: Novel E3 Ligases and Pre-PROTACs. | J Med Chem | 2026 | 41930897 | PubTator, text mining | PubMed |
| Protein arginine methyltransferases in cancer: mechanisms, functions, and therapeutic opportunities. | J Biomed Sci | 2026 | 41928257 | PubTator, text mining | PubMed |
| Insights into the Design of MYC-Targeting Proteolysis Targeting Chimeras (PROTACs). | Molecules | 2026 | 41900110 | PubTator, text mining | PubMed |
| A dihydrouracil CRBN ligand mitigates IMiD associated safety liabilities in heterobifunctional targeted protein degrader. | Nat Commun | 2026 | 41876537 | PubTator, text mining | PubMed |
| Targeting CRBN With Thalidomide Suppresses Fibrosis After Glaucoma Drainage Surgery Through NF-κB Pathway Inhibition. | Invest Ophthalmol Vis Sci | 2026 | 41860320 | PubTator, text mining | PubMed |
| The JMJD family histone demethylases: structure, mechanism of action, diseases and therapeutic targets. | Mol Biomed | 2026 | 41857315 | PubTator, text mining | PubMed |
| The Future of Epigenetics: Emerging Technologies and Clinical Applications. | ACS Pharmacol Transl Sci | 2026 | 41852637 | PubTator, text mining | PubMed |
| Prospects and advances of PROTAC in the treatment of hematologic malignancies. | Exp Hematol Oncol | 2026 | 41845415 | PubTator, text mining | PubMed |
| AI-Based Prediction of PROTAC- and Molecular Glue-Mediated Ternary Complexes: A Comparative Evaluation of AlphaFold 3 and Boltz-2. | Arch Pharm (Weinheim) | 2026 | 41831109 | PubTator, text mining | PubMed |
| Discovery of the First-in-Class Protein Arginine Methyltransferase 1 PROTAC Degrader. | J Med Chem | 2026 | 41830641 | PubTator, text mining | PubMed |
| Targeted Degradation of Dipeptidyl Peptidase-4 via Proteolysis-Targeting Chimera Technology for Sustained Glycemic Control in Type 2 Diabetes. | J Med Chem | 2026 | 41823561 | PubTator, text mining | PubMed |
| Advances in molecular glue degraders for targeted protein degradation: Focus on NEK7, WEE1, CDK2, GSPT1 and VAV1. | Asian J Pharm Sci | 2026 | 41810469 | PubTator, text mining | PubMed |
| Novel Small Molecule DZ-865B Effectively Degrades BCL6, Promotes Apoptosis and Reduces Proliferation of Diffuse Large B-Cell Lymphoma Cells. | Oncol Res | 2026 | 41799511 | PubTator, text mining | PubMed |
| Flow-induced Klf4-Akt signaling links EC cycling to mural cell defects in arterial-venous malformations. | Theranostics | 2026 | 41799188 | PubTator, text mining | PubMed |
| Quantitative analysis of ternary complex kinetics by a surface immobilization method. | Biochem Biophys Res Commun | 2026 | 41793853 | PubTator, text mining | PubMed |
| Decoding organ fibrosis: mechanistic insights and emerging therapeutic strategies. | Signal Transduct Target Ther | 2026 | 41786685 | PubTator, text mining | PubMed |
| PROTAC-mediated degradation of peroxisomal d-aspartate oxidase: A novel strategy to modulate d-aspartate homeostasis for schizophrenia treatment. | Eur J Med Chem | 2026 | 41785830 | PubTator, text mining | PubMed |
| Histone deacetylases: Function in tumor development and therapeutic prospects (Review). | Oncol Lett | 2026 | 41783166 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=5